Paion AG

PAION reported 2021 revenue of €7.1 million, consisting of €4.5 million from remimazolam API and royalties and €2.6 million from upfront and milestone payments. R&D expense was €5.2 million, down by €5 million versus 2020, while SG&A rose to €19.8 million, with general and administrative expense at €5.5 million and selling expense at €14.3 million. Net loss was €21.8 million versus net income of €2.2 million in the prior year; cash and cash equivalents were €6.4 million at year-end, equity was €7 million, and the equity ratio fell to 19% from 76%. For 2022, management guided to revenue of about €32 million to €35 million, cost of revenues of about €5 million to €6 million, net SG&A of about €26 million to €29 million, R&D of about €7 million to €9 million, and EBITDA of minus €9 million to minus €2.5 million. Of expected 2022 revenue, roughly €25 million to €27 million is expected from existing licenses, including €20.5 million from the Humanwell patent assignment and €4.5 million to €6.5 million from remimazolam API and royalties, plus about €2 million to €3 million from own commercialization and about €5 million from out-licensing.

Jim Phillips framed 2021 as a transformation year and 2022 as the start of execution, saying PAION is becoming a commercial-stage specialty pharmaceutical company focused on anesthesia and critical care. He emphasized progress across the product portfolio, including launches of Byfavo, GIAPREZA and XERAVA, and said the company expects profitability in 2024. His tone was optimistic but measured: he noted the business is still in an investment phase and said investors should not expect too much too early.

Abdelghani Omari highlighted a mixed financing picture in 2021: a €20 million EIB loan, a small capital increase with gross proceeds of €7.8 million, and then the post-period €20.5 million sale of the Chinese remimazolam patent and royalty stream to Humanwell as nondilutive funding. He said PAION expects sufficient liquidity for the next 12 months, but still needs approximately €30 million to reach break-even based on current planning. On the P&L, he cited €7.1 million of revenue, €5.2 million of R&D, €19.8 million of SG&A, and a net loss of €21.8 million; he also noted operating cash flow of minus €21.2 million, investing cash flow of minus €19.2 million, and positive financing cash flow of €27.1 million.

Analysts focused on GIAPREZA’s positioning in distributive shock, the East European distribution deal, possible South America out-licensing, Canada, and funding strategy. Management said GIAPREZA is not necessarily replacing vasopressin but may fit as a second-line therapy in certain patients, and confirmed the Medis East Europe deal included a small undisclosed upfront because it is a distributor arrangement. On Canada, Jim Phillips said the prior deal with Pharmascience was mutually terminated because of pricing and commercial viability issues, and he expressed confidence that PAION can find a better partner. In a later exchange, management said nondilutive financing is preferred, Cosmo has started trimming its stake, and Eagle’s larger U.S. commercial infrastructure could accelerate Byfavo uptake once the Acacia transaction closes, though there may be short-term disruption while the deal is pending.